AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
ASTRAZENECA PLC
Financials through Q2 FY2026, quarter ended Jun 30, 2026
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026
- Market cap
- $255.76B
- P/E (TTM)
- 25.1
- Dividend yield
- 1.91%
ASTRAZENECA PLC revenue by segment
By business segment
By product or service
| Revenue | Q4 25 | Q4 24 | Q4 23 | Q4 22 | Q2 22 | Q4 21 | Q2 21 | Q1 21 | Q4 20 | Q3 20 | Q2 20 | Q1 20 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BioPharmaceuticals: total CVRM | – | – | – | – | – | – | $2.02B | $1.91B | $1.84B | $1.79B | $1.76B | $1.70B | – | – |
| Other CVRM | – | – | – | – | – | – | $47.00M | $51.00M | $46.00M | $39.00M | $48.00M | $59.00M | – | – |
| Tagrisso | – | – | – | – | – | – | $1.31B | $1.15B | $1.16B | $1.16B | $1.03B | $982.00M | – | – |
| Bevespi | – | – | – | – | – | – | $13.00M | $13.00M | $12.00M | $14.00M | $10.00M | $12.00M | – | – |
| Imfinzi | – | – | – | – | – | – | $604.00M | $556.00M | $555.00M | $533.00M | $492.00M | $462.00M | – | – |
| Calquence | – | – | – | – | – | – | $280.00M | $209.00M | $182.00M | $145.00M | $107.00M | $88.00M | – | – |
| Fasenra | – | – | – | – | – | – | $320.00M | $260.00M | $283.00M | $240.00M | $227.00M | $199.00M | – | – |
| Onglyza | – | – | – | – | – | – | $99.00M | $101.00M | $105.00M | $110.00M | $115.00M | $141.00M | – | – |
| Arimidex | – | – | – | – | – | – | $29.00M | $44.00M | $36.00M | $42.00M | $58.00M | $50.00M | – | – |
| Atacand | – | – | – | – | – | – | $23.00M | $34.00M | $63.00M | $54.00M | $59.00M | $66.00M | – | – |
| Brilinta | – | – | – | – | – | – | $375.00M | $374.00M | $363.00M | $385.00M | $437.00M | $408.00M | – | – |
| Bydureon | – | – | – | – | – | – | $95.00M | $103.00M | $122.00M | $109.00M | $116.00M | $100.00M | – | – |
| Byetta | – | – | – | – | – | – | $16.00M | $16.00M | $19.00M | $15.00M | $15.00M | $20.00M | – | – |
| Casodex | – | – | – | – | – | – | $41.00M | $42.00M | $39.00M | $44.00M | $47.00M | $42.00M | – | – |
| Crestor | – | – | – | – | – | – | $265.00M | $274.00M | $298.00M | $300.00M | $281.00M | $301.00M | – | – |
| Daliresp/Daxas | – | – | – | – | – | – | $54.00M | $60.00M | $54.00M | $57.00M | $53.00M | $53.00M | – | – |
| Farxiga | – | – | – | – | – | – | $732.00M | $624.00M | $586.00M | $525.00M | $443.00M | $405.00M | – | – |
| Faslodex | – | – | – | – | – | – | $105.00M | $122.00M | $130.00M | $138.00M | $146.00M | $166.00M | – | – |
| Iressa | – | – | – | – | – | – | $47.00M | $61.00M | $67.00M | $54.00M | $70.00M | $77.00M | – | – |
| Losec/Prilosec | – | – | – | – | – | – | $46.00M | $54.00M | $39.00M | $45.00M | $45.00M | $54.00M | – | – |
| Lynparza | – | – | – | – | – | – | $588.00M | $543.00M | $496.00M | $464.00M | $419.00M | $397.00M | – | – |
| Nexium | – | – | – | – | – | – | $336.00M | $403.00M | $377.00M | $401.00M | $377.00M | $338.00M | – | – |
| Total Oncology | – | – | – | – | – | – | $3.29B | $2.98B | $2.91B | $2.83B | $2.61B | $2.50B | – | – |
| Other Oncology | – | – | – | – | – | – | $13.00M | $12.00M | $13.00M | $13.00M | $12.00M | $13.00M | – | – |
| Total Other medicines | – | – | – | – | – | – | $454.00M | $548.00M | $733.00M | $734.00M | $563.00M | $557.00M | – | – |
| Other, Others | – | – | – | – | – | – | $26.00M | $36.00M | $41.00M | $19.00M | $24.00M | $44.00M | – | – |
| Other R&I | – | – | – | – | – | – | $130.00M | $160.00M | $125.00M | $90.00M | $70.00M | $113.00M | – | – |
| Pulmicort | – | – | – | – | – | – | $167.00M | $330.00M | $368.00M | $151.00M | $97.00M | $380.00M | – | – |
| BioPharmaceuticals: total Respiratory & Immunology | – | – | – | – | – | – | $1.42B | $1.54B | $1.53B | $1.16B | $1.12B | $1.55B | – | – |
| Seloken/Toprol-XL | – | – | – | – | – | – | $266.00M | $250.00M | $200.00M | $225.00M | $218.00M | $177.00M | – | – |
| Symbicort | – | – | – | – | – | – | $680.00M | $691.00M | $680.00M | $599.00M | $653.00M | $790.00M | – | – |
| Synagis | – | – | – | – | – | – | $24.00M | $24.00M | $78.00M | $118.00M | $90.00M | $85.00M | – | – |
| Zoladex | – | – | – | – | – | – | $244.00M | $221.00M | $216.00M | $230.00M | $217.00M | $225.00M | – | – |
| Seroquel XR/IR | – | – | – | – | – | – | $21.00M | $29.00M | $19.00M | $35.00M | $27.00M | $36.00M | – | – |
| Other diabetes | – | – | – | – | – | – | $15.00M | $13.00M | $12.00M | $11.00M | $10.00M | $13.00M | – | – |
| Breztri | – | – | – | – | – | – | $56.00M | $27.00M | $6.00M | $10.00M | $7.00M | $4.00M | – | – |
| Lokelma | – | – | – | – | – | – | $39.00M | $33.00M | $28.00M | $21.00M | $17.00M | $11.00M | – | – |
| Koselugo | – | – | – | – | – | – | $26.00M | $21.00M | $17.00M | $13.00M | $7.00M | – | – | – |
| FluMist | – | – | – | – | – | – | $1.00M | $2.00M | $179.00M | $116.00M | – | – | – | – |
| Pandemic COVID-19 Vaccine | – | – | – | – | – | – | $862.00M | $275.00M | – | – | – | – | – | – |
| roxadustat | – | – | – | – | – | – | $51.00M | $39.00M | – | – | – | – | – | – |
| Enhertu | – | – | – | – | – | – | $3.00M | $1.00M | – | – | – | – | – | – |
| COVID 19 | – | – | – | – | – | – | $862.00M | $275.00M | – | – | – | – | – | – |
By region
| Revenue | Q4 25 | Q4 24 | Q4 23 | Q4 22 | Q2 22 | Q4 21 | Q2 21 | Q1 21 | Q4 20 | Q3 20 | Q2 20 | Q1 20 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Europe | – | – | – | – | $2.06B | – | $1.70B | – | – | – | $1.10B | – | – | – |
| US | – | – | – | – | $4.25B | – | $2.47B | – | – | – | $2.01B | – | – | – |
| Emerging Markets | – | – | – | – | $2.78B | – | $2.83B | – | – | – | $2.05B | – | – | – |
| Rest of World | – | – | – | – | $10.63B | – | $8.05B | – | – | – | $6.05B | – | – | – |
| Established ROW | – | – | – | – | $1.55B | – | $1.04B | – | – | – | $885.00M | – | – | – |
From the segment and revenue-disaggregation notes of Astrazeneca's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.